

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Full title: Hearing loss at 6-monthly assessments from age 12 to 36 months: secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.

Short title: Hearing loss at 6-monthly assessments from age 12 to 36 months

A.J. Leach^{1*}, N. Wilson¹, B. Arrowsmith^{1,2}, J. Beissbarth¹, E.K. Mulholland^{3,4,5}, M. Santosham^{6,7}, P.J. Torzillo^{8,9}, P. McIntyre^{10,11}, H. Smith-Vaughan¹, S.A. Skull¹², V.M. Oguoma^{1,13}, M.D. Chatfield^{1,14}, D. Lehmann², C. G. Brennan-Jones^{2,15}, M. J. Binks^{1,16}, P.V. Licciardi^{4,5}, R. Andrews¹⁷, T. Snelling¹⁸, V. Krause¹⁹, J. Carapetis^{2,12}, A.B. Chang^{1,20}, P.S. Morris^{1,21}

¹Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia

²Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia

³London School of Hygiene and Tropical Medicine, London, United Kingdom

⁴Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia

⁵Murdoch Children's Research Institute, Melbourne, Victoria, Australia

⁶Departments of International Health and Pediatrics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America

⁷Center for Indigenous Health, Johns Hopkins University, Baltimore, United States of America

⁸Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

⁹Department of Medicine, University of Sydney, Sydney, New South Wales, Australia

¹⁰Discipline of Child and Adolescent Health, University of Sydney, New South Wales, Australia

¹¹Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

¹²Division of Paediatrics and Child Health, University of Western Australia, Australia

¹³Poche Centre for Indigenous Health, The University of Queensland, Brisbane, Queensland, Australia

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
¹⁴Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia

- 29 ¹⁵School of Allied Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia
- 30 ¹⁶Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide,
31 Australia
- 32 ¹⁷Office of the Chief Health Officer, Queensland Health, Brisbane, Queensland, Australia
- 33 ¹⁸School of Public Health, University of Sydney, Sydney, New South Wales, Australia
- 34 ¹⁹Centre for Disease Control (CDC)-Environmental Health, Northern Territory Health, Darwin,
35 Northern Territory, Australia
- 36 ²⁰Australian Centre for Health Services Innovation, Queensland University of Technology, Brisbane,
37 Queensland, Australia
- 38 ²¹Royal Darwin Hospital, Paediatrics Department, Darwin, Northern Territory, Australia
39
- 40 ¹Professor Amanda Jane Leach*, PhD; amanda.leach@menzies.edu.au
- 41 ¹Nicole Wilson, MPH; nictwil1136@gmail.com
- 42 ^{1,2}Beth Arrowsmith, RN; Beth.Arrowsmith@yahoo.com
- 43 ¹Dr Jemima Beissbarth, PhD; Jemima.Beissbarth@menzies.edu.au
- 44 ^{3,4,5}Professor Edward Kim Mulholland, MD; Kim.Mulholland@lshtm.ac.uk
- 45 ^{6,7}Professor Mathuram Santosham, MBBS; Msantosham@jhu.edu
- 46 ^{8,9}Professor Paul John Torzillo, MBBS; paul.torzillo@sydney.edu.au
- 47 ^{10,11}Professor Peter McIntyre, PhD; peter.mcintyre@otago.ac.nz
- 48 ¹Professor Heidi Smith-Vaughan, PhD; heidi.smith-vaughan@menzies.edu.au
- 49 ¹²Associate Professor Sue A Skull, PhD; Sue.skull@uwa.edu.au
- 50 ^{1,13}Dr Victor M Oguoma, PhD; victor.oguoma@menzies.edu.au
- 51 ^{1,14}Associate Professor Mark D. Chatfield, MSc; m.chatfield@uq.edu.au
- 52 ²Clinical Associate Professor Deborah Lehmann, MBBS; Deborah.lehmann@telethonkids.org.au
- 53 ^{2,15} Associate Professor Christopher G. Brennan-Jones, PhD; chris.brennan-jones@telethonkids.org.au
- 54 ^{1,16}Dr Michael J. Binks, PhD; Michael.Binks@menzies.edu.au
- 55 ^{3,4}Associate Professor Paul V Licciardi, PhD; paul.licciardi@mcri.edu.au
- 56 ¹⁷Professor Ross Andrews, PhD; Ross.Andrews2@health.qld.gov.au

57 ¹⁸Professor Tom Snelling, PhD; tom.snelling@sydney.edu.au
58 ¹⁹Associate Professor Vicki Krause, MD; vicki.krause@nt.gov.au
59 ^{2,12}Professor Jonathan Carapetis, PhD; Jonathan.Carapetis@telethonkids.org.au
60 ^{1,20}Professor Anne B Chang, PhD; Anne.chang@menzies.edu.au
61 ^{1,21}Professor Peter Stanley Morris, PhD. Peter.morris@menzies.edu.au

62

63

64 Correspondence to:

65 *Professor Amanda Jane Leach AM

66 Menzies School of Heath Research, Charles Darwin University

67 PO Box 41096

68 Casuarina, 0811

69 Northern Territory

70 Australia

71 amanda.leach@menzies.edu.au

72 **+61 8 89468560**

73 **+61 408086291**

74

75

76 **Abstract 296 words**

77 **Introduction:** In remote communities, Australian First Nations children with hearing loss are
78 disproportionately at risk of poor school readiness and performance, compared to those with normal
79 hearing. Our objective was to compare two pneumococcal conjugate vaccine (PCV) formulations and
80 mixed schedules (the PREVIX trials) designed to broaden protection and reduce conductive hearing
81 loss to age 36 months.

82
83 **Methods:** In two sequential parallel, open-label, randomised controlled trials, eligible infants were first
84 allocated 1:1:1 at age 28-38 days to standard or mixed PCV primary schedules, then at age 12 months
85 to a booster dose (1:1) of PCV13 (13-valent pneumococcal conjugate vaccine, +P) or PHiD-CV10 (10-
86 valent pneumococcal *Haemophilus influenzae* protein D conjugate vaccine, +S). Here we report
87 secondary hearing outcomes in the +P and +S groups at 6-monthly scheduled assessments from age 12
88 to 36 months.

89
90 **Findings:** From March 2013 to September 2018, 461 hearing assessments were performed. Prevalence
91 of mild- moderate hearing loss declined in both groups from ~75% at age 12 months to ~53% at 36
92 months. At primary endpoint age 18 months, prevalence of moderate (disabling) hearing loss was 21%
93 and 41% in the +P and +S groups, respectively (difference -19% [95% confidence interval -38, -1],
94 $p=0.07$) and prevalence of normal hearing was 36% and 16%, respectively (difference 19% [95%CI 2,
95 37], $p=0.05$). At subsequent timepoints prevalence of moderate hearing loss remained lower in the +P
96 group at -3% [95% CI -23, 18] at age 24 months, -12% [95%CI -30, 6] at 30 months, and -9% [95%CI
97 -23, 5] at 36 months.

98
99 **Interpretation:** This study provides first evidence of the high prevalence and persistence of mild and
100 moderate hearing loss throughout early childhood. A lower prevalence of moderate (disabling) hearing
101 loss in the +P group may have substantial benefits for high-risk children and warrants further
102 investigation.

103

104 **Trial registration:** ClinicalTrials.gov NCT01735084 and NCT01174849

105 <https://clinicaltrials.gov/study/NCT01735084> <https://clinicaltrials.gov/study/NCT01174849>

106 **Funding:** National Health and Medical Research Council of Australia (GNT605810, GNT1046999,
107 GNT1120353)

108 **Key words:** pneumococcal conjugate vaccine; randomised controlled trial; conductive hearing loss;
109 child; Aboriginal; First Nations; Australia.

110 **ALL TEXT 2657 words**

111 **Introduction**

112 **Background and objectives:**

113 Australian First Nations children living in remote communities continue to experience social and
114 educational disadvantage[1] which can be attributed in part to preventable hearing loss associated with
115 early onset of persistent otitis media (OM). *Streptococcus pneumoniae* (pneumococcus) and non-
116 typeable *Haemophilus influenzae* (NTHi) are dominant pathogens of OM from soon after birth.[2]

117 The Northern Territory (NT) childhood vaccination schedule replaced seven-valent pneumococcal
118 conjugate vaccine (PCV7) with ten-valent pneumococcal *Haemophilus influenzae* protein D conjugate
119 vaccine (S, PHiD-CV10) in 2009, then 13-valent PCV (P, PCV13) vaccine in 2011. Our surveillance
120 studies found evidence of less AOM and a lower prevalence of NTHi in ear discharge of PHiD-CV10-
121 vaccinated compared to PCV7-vaccinated First Nations children.[2, 3]

122 Our objective was to conduct two sequential randomised controlled trials (RCTs) of primary- and
123 booster- head-to-head and combination schedules of PCV13 and PHiD-CV10; PREVIX_COMBO[4,
124 5] and PREVIX_BOOST,[6] PREVIX being a name representing the two PCV brand names.

125 We hypothesised that infants receiving PHiD-CV10 compared with those receiving PCV13 as a
126 booster at 12 months of age would have (i) superior immunogenicity at 18 months of age for common
127 serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F), and at ages 18, 24, 30 and 36 months of age,
128 infants receiving PHiD-CV10 compared with those receiving PCV13 as a booster at 12 months of age

129 would have (ii) less nasopharyngeal carriage of NTHi; (iii) more NP carriage of serotypes 3, 6A and
130 19A; (iv) less NP carriage of common serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F); (v) less
131 NP carriage of vaccine- related or nonvaccine (replacement) serotypes; (vi) less OM; (vii) less
132 respiratory illness; (viii) less hearing loss and (ix) less developmental delay.[7] We have reported co-
133 primary and select secondary outcomes to age 18 months,[4, 6, 8] and otitis media to age 36 months.[9]
134 This study, PREVIX_VOICES (Vaccines for Otitis In Children Entering School) builds on
135 PREVIX_BOOST through added capacity to employ paediatric audiologists to conduct 6-monthly
136 hearing tests from age 12 to 36 months. Here we report new data on vaccine group comparisons of
137 hearing level and prevalence of hearing loss.

138

139 **Methods**

140 Details of PREVIX_COMBO and PREVIX_BOOST (including PREVIX_VOICES) protocols have
141 been published.[5, 7] Brief methods relevant to hearing outcomes from age 12 to 36 months are
142 described below.

143

144 **Study design**

145 The PREVIX_COMBO and PREVIX_BOOST trials were primary outcome assessor-blinded, three-
146 arm (1:1:1) and two-arm (1:1) parallel RCTs. PREVIX_VOICES added capacity to obtain the hearing
147 outcomes for all children in the PREVIX_BOOST study, and additional scheduled 6-monthly
148 assessments at ages 24 to 30 months. No changes that affected the primary objectives or outcomes were
149 made after trial commencement.

150

151 **Participants**

152 First Nations children were eligible for PREVIX_BOOST if they were 12 months of age, had
153 previously enrolled in the PREVIX_COMBO three-arm RCT, and were living in one of three remote
154 Aboriginal communities in the NT or a single Western Australian community. PREVIX_VOICES
155 evaluated hearing outcomes in all PREVIX-enrolled children living in the three NT communities.

156

157 **Randomisation and masking**

158 Sequence generation: After confirming eligibility and obtaining informed consent, research nurses
159 called the 24/7 randomisation service of the National Health and Medical Research Council Clinical
160 Trial Centre to obtain allocation. Stratification by remote community was applied in both trials, and for
161 PREVIX_BOOST, minimisation by PREVIX_COMBO group was applied. This open-label design did
162 not allow for blinding.

163

164 **Procedures**

165 PHiD-CV10 contains 10 pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and
166 incorporates protein D of NTHi as a carrier protein for eight serotypes. PCV13 contains these ten and
167 additional serotypes 3, 6A, and 19A, but does not incorporate protein D.

168 Audiology assessments were initially made by fly-in/fly-out NT Government Hearing Health
169 Program audiologists. Paediatric audiologists dedicated to assessment of hearing in the
170 PREVIX_VOICES study commenced in March 2017. All assessments were conducted in the child's
171 community, in sound-treated hearing booths using an audiometer (Interacoustics paediatric audiometer
172 (PA5) or Otometrics MADSEN Itera II). Hearing responses were tested using Visual Reinforcement
173 Observation Audiometry (VROA) in the sound-field or Play Audiometry using headphones. The pure-
174 tone four-frequency average (4fa) hearing level (in decibels, dB HL) was calculated for air conduction
175 thresholds binaural or monaurally using up to four frequencies 0.5, 1.0, 2.0, and 4.0 kHz (i.e. $\leq 4fa$).
176 Categories of hearing response (hereafter referred to as hearing loss) were no or slight hearing loss (\leq
177 0 to 20 dB), mild (21 to 30 dB), moderate (31 to 60 dB), severe (61 to 90 dB), or profound (>90 dB)
178 hearing loss.[10] We also report the proportion with mean hearing level (3fa) greater than 23.3 dB,
179 which is the Hearing Australia threshold for hearing assistance.[11] All child-visits included a general
180 health check, with management according to local guidelines.[12, 13]

181

182 **Analysis and statistical methods**

183 Sample sizes of 425 and 270 were estimated for primary outcomes (immunogenicity) of the
184 PREVIX_COMBO and PREVIX_BOOST, respectively.[4, 6] Analyses of secondary outcome data
185 available at each time point are according to allocated group. We did not impute any data. All data were
186 analysed using Stata/IC version 15.1[14] Baseline characteristics are reported for each
187 PREVIX_BOOST group using means and standard deviation for continuous data if assumption of
188 normal distribution was met, otherwise median value and IQR are reported. Categorical data are
189 summarised as percentages. Vaccine group differences in percentages are compared with two-sided
190 Clopper-Pearson 95% Confidence Interval (95%CI, Fisher's Exact p value) and differences in mean
191 hearing level as two-sample t-test with equal variances.

192

193 **Role of funding source**

194 The funders had no role in study design, data collection, data analysis, data interpretation, or writing
195 of the report.


196

197 **Results**

198 The PREVIX_BOOST trial commenced participant recruitment in March 2013. Hearing tests were
199 performed by the NT Government Hearing Services outreach program if possible. Research
200 audiologists commenced in March 2017. Data collection was completed in September 2018.

201 At baseline age 12 months, 131 children were allocated to +P and 130 to +S; one child allocated to
202 +P received +S and was included in the +P group for analysis. The numbers of children seen and
203 assessed for hearing outcome are given in Fig 1 and Table 1. Of 461 hearing tests, 409 (89%) were
204 VROA and 52 (11%) Play Audiometry; 74% were performed by research audiologists. Due to the late
205 start of research audiologists, only 23% to 35% PREVIX_BOOST children were age-eligible for the
206 12- and 18-month hearing assessments, respectively, and around half (58%) had hearing tests at age 36
207 months. For the additional study visits at ages 24 and 30 months, almost all age-eligible children had
208 hearing assessments (Table 2, Fig 1).

209 **Fig 1 Participant Flow**



210

211 There were no significant vaccine inter-group differences in characteristics of children in the hearing
 212 cohort at any age, other than at age 24 months when the +S group had a higher baseline proportion of
 213 siblings with “runny ears” (32%) than the +P group (13%), and at age 36 months when the +S group
 214 had a higher baseline proportion of breast feeding in infancy (73%) than the +P group (52%). (Table 1)

215

216

217

Table 1. Baseline characteristics and risk factors for the hearing cohort at each study visit age.

Vaccine group		+P	+S	+P	+S	+P	+S	+P	+S	+P	+S
Age at hearing test, months (SD)		12·7 (1·1)	12·6 (1·4)	18·4 (1·1)	18·5 (1·4)	24·1 (1·2)	24·3 (1·2)	30·2 (1·5)	30·3 (1·4)	36·9 (1·9)	36·9 (1·8)
N		32	28	42	49	47	39	55	56	54	59
Sex	male	16/32 (50%)	14/28 (50%)	19/42 (45%)	24/49 (49%)	22/47 (47%)	19/39 (49%)	29/55 (53%)	36/56 (64%)	27/54 (50%)	37/59 (63%)
Gestational age at birth, weeks (SD)		38·2 (1·2)	38·1 (2·0)	38·3 (1·2)	38·0 (1·7)	37·9 (1·5)	38·2 (1·7)	38·1 (1·2)	38·1 (1·5)	38·0 (1·5)	38·2 (1·5)
Birth weight, Kg (SD)		3·08 (0·48)	3·17 (0·49)	3·06 (0·49)	3·17 (0·49)	3·13 (0·56)	3·13 (0·44)	3·02 (0·48)	3·11 (0·46)	3·14 (0·52)	3·12 (0·38)
Any otitis media (otoscopy and tympanometry)	Yes	25/30 (83%)	25/26 (96%)	38/41 (93%)	43/48 (90%)	31/42 (74%)	31/35 (89%)	39/53 (76%)	40/50 (80%)	30/51 (59%)	39/56 (70%)
Were you breastfeeding?	Yes	31/32 (97%)	25/27 (93%)	30/35 (86%)	34/41 (83%)	38/46 (83%)	30/39 (77%)	37/55 (67%)	43/55 (78%)	28/54 (52%)	43/59 (73%)
Community	Wurrumiyanga	11/32 (34%)	8/28 (29%)	10/42 (24%)	14/49 (29%)	15/47 (32%)	12/39 (31%)	13/55 (24%)	16/56 (29%)	11/54 (20%)	16/59 (27%)
	Wadeye	14/32 (44%)	13/28 (46%)	22/42 (52%)	20/49 (41%)	20/47 (43%)	14/39 (36%)	21/55 (38%)	23/56 (41%)	26/54 (48%)	26/59 (44%)
	Maningrida	7/32 (22%)	7/28 (25%)	10/42 (24%)	15/49 (31%)	12/47 (26%)	13/39 (33%)	21/55 (38%)	17/56 (30%)	17/54 (31%)	17/59 (29%)
How many children under age 5 years live with you and your baby?	0	14/32 (44%)	11/28 (39%)	18/42 (43%)	20/49 (41%)	25/47 (53%)	20/39 (51%)	28/55 (51%)	23/56 (41%)	20/54 (37%)	28/59 (47%)
	1	10/32 (31%)	5/28 (18%)	15/42 (36%)	13/49 (27%)	12/47 (26%)	12/39 (31%)	14/55 (25%)	18/56 (32%)	17/54 (31%)	18/59 (31%)
	>1	8/32 (25%)	12/28 (43%)	9/42 (21%)	16/49 (33%)	10/47 (21%)	7/39 (18%)	13/55 (24%)	15/56 (27%)	17/54 (31%)	13/59 (22%)
Have any of your other children had runny ears?	Yes	3/21 (14%)	3/23 (13%)	7/33 (21%)	10/36 (28%)	5/40 (13%)	10/31 (32%)	9/45 (20%)	13/43 (30%)	12/49 (24%)	8/48 (17%)
Has your baby had any bad runny nose since the last study visit?	Yes	12/32 (38%)	12/28 (43%)	19/42 (45%)	29/48 (60%)	19/47 (40%)	17/39 (44%)	27/55 (49%)	21/56 (38%)	23/53 (43%)	35/59 (59%)
Do you smoke cigarettes?	Yes	20/32 (63%)	17/27 (63%)	27/41 (66%)	27/48 (56%)	28/46 (61%)	23/39 (59%)	36/55 (65%)	35/54 (65%)	37/54 (69%)	36/59 (61%)

218

219


220 Table 2. Proportion of children with hearing loss by category (normal, mild, moderate, severe),
 221 hearing loss above 23.3 dB, and mean hearing loss (dB, SD) at ages 12 (baseline), 18, 24, 30, and 36
 222 months, by booster dose (difference, 95%CI, p value). (N=461)

Visit age (months)	Hearing response category or response level (4fa dB, SD)	Total	+P	+S	DIFF +P - +S	95%CI	P value
12	tested	60/261(23%)	32/131 (24%)	28/130 (22%)	3%	-7, 13	0.66
	none	15 (25%)	7/32 (22%)	8/28 (29%)	-7%	-29, 15	0.57
	mild	20 (33%)	11 (34%)	9 (32%)	2%	-22, 26	1.00
	moderate	25 (42%)	14 (44%)	11 (39%)	4%	-20, 29	0.80
	>23.3 (3fa)	40 (67%)	22 (69%)	18 (64%)	4%	-19, 28	0.79
	Mean dB (SD)	29.5 (8.4)	29.5 (8.2)	29.5 (8.8)	0.02 dB	-4.4, 4.4	1.00
18	tested	91/257(35%)	42/129 (33%)	49/128 (38%)	-6%	-17, 6	0.36
	none	23/91 (25%)	15 (36%)	8 (16%)	19%	2, 37	0.05
	mild	39 (43%)	18 (43%)	21 (43%)	0%	-20, 20	1.00
	moderate	29 (32%)	9 (21%)	20 (41%)	-19%	-38, -1	0.07
	>23.3 (3fa)	63 (69%)	26 (62%)	37 (76%)	-14%	-33, 5	0.18
	Mean dB (SD)	28.0 (7.9)	26.2 (6.9)	29.6 (8.4)	-3.4 dB	-6.7, -0.2	0.04
24	tested	86/98 (88%)	47/48 (98%)	39/50 (78%)	20%	8, 32	0.004
	none	19 (22%)	11 (23%)	8 (21%)	3%	-15, 20	0.80
	mild	38 (44%)	21 (45%)	17 (44%)	-1%	-20, 22	1.00
	moderate	29 (34%)	15 (32%)	14 (36%)	-3%	-23, 18	1.00
	>23.3 (3fa)	61 (71%)	31 (66%)	30 (77%)	-11%	-30, 8	0.34
	Mean dB (SD)	28.9 (9.4)	27.7 (8.1)	30.3 (10.7)	-2.6 dB	-6.7, 1.4	0.2
30	tested	111/111 (100%)	55/55 (100%)	56/56 (100%)	0%	na	na
	none	35 (34%)	24 (44%)	18 (32%)	12%	-6, 29	0.24
	mild	32 (29%)	16 (29%)	16 (29%)	0%	-16, 17	1.00
	moderate	37 (33%)	15 (27%)	22 (39%)	-12%	-30, 6	0.29
	>23.3 (3fa)	56 (50%)	26 (47%)	30 (54%)	-6%	-25, 12	0.57
	Mean dB (SD)	26.9 (9.4)	26.0 (8.7)	27.8 (10.05)	-1.9 dB	-5.4, 1.7	0.30
36	tested	113/196 (58%)	54/91 (59%)	59/105 (56%)	3%	-11, 17	0.67
	none	52 (42%)	26 (48%)	25 (42%)	6%	-14, 14	0.57
	mild	39 (34%)	20(37%)	19 (32%)	5%	-13, 22	0.69
	moderate	22 (19%)	8 (15%)	14 (24%)	-9%	-23, 5	0.25
	severe	1 (0.6%)	0 (0%)	1 (1.7%)	-1%	-3, 1	1.00
	>23.3 (3fa)	49 (43%)	22 (41%)	27 (45%)	-4%	-22, 14	0.71
Mean dB (SD)	24.5 (10.4)	22.8 (7.2)	25.9 (12.5)	-3.1 dB	-7.0, 0.7	0.11	

223
 224 **Bold** indicates significant vaccine group difference p<0.05
 225 +P: booster dose of PCV13 13-valent Pneumococcal conjugate vaccine
 226 +S: booster dose of PHiD-CV10 10-valent Pneumococcal *H. influenzae* protein D conjugate vaccine
 227 dB: decibel
 228 SD: standard deviation
 229 Hearing loss categories: none ≤ 20dB. Mild 21 to 30 dB. Moderate 31 to 60 dB. Severe 61 to 90 dB. Profound > 90 dB
 230 4fa: average of up to 4 frequencies (500, 1000, 2000, and 4000 Hertz)
 231 >23.3 (3fa): Hearing Australia threshold for hearing assistance
 232 CI: Confidence Interval
 233 P value. 2-sided Fisher's exact, or ttest
 234

235

236 Fig 2: Hearing loss prevalence (normal, mild, moderate, severe) by booster dose, at ages 12
 237 (baseline), 18 (primary endpoint), 24, 30, and 36 months



238

239

240

241 +P: booster dose of PCV13 13-valent Pneumococcal conjugate vaccine
 242 +S: booster dose of PHiD-CV10 10-valent Pneumococcal *H. influenzae* protein D conjugate vaccine
 243

244 At baseline age 12 months, 32/131 (24%) and 28/130 (22%) children in the +P and +S groups
 245 respectively had hearing tests; hearing loss was similar in both groups (Table 2, Fig 2). At age 18
 246 months, six months post booster dose, 42 and 49 children had hearing tests in the +P and +S groups,
 247 respectively; 36% and 16%, respectively had no hearing loss (difference 19% [95%CI 2, 37], p=0.05);
 248 43% in each group had mild hearing loss, and 21% and 41%, respectively had moderate hearing loss
 249 (difference -19% [95%CI -38, -1], p=0.07) (Table 2, Fig 2). Mean hearing level was 26.2 dB in the +P
 250 group and 29.6 dB in the +S group (difference -3.4 dB ([95%CI -6.7, -0.2] p=0.04) (Table 2); 62%
 251 children in the +P group and 76% in the +S group met the Hearing Australia threshold for hearing

252 assistance (mean hearing level (3fa) greater than 23.3 dB)[11] (difference -14%, [95%CI -33, 5]
253 p=0.18).(Table 2)

254 At ages 24, 30, and 36 months, the proportion of children with no hearing loss was higher, mean
255 hearing level and moderate hearing loss tended to be lower in the +P group.-(Table 2, Fig 2)

256 Analysis stratified by allocation to three primary course schedules in PREVIX_COMBO indicated
257 that the lower prevalence of moderate hearing loss in the +P group at age 18 months was present in all
258 subgroups (differences -8% between _PPP+P and _PPP+S, -5% between _SSS+P and _SSS+S, and -
259 15% between SSSP+P and SSSP+S). The greatest difference was between SSSP+P (23%) and SSSP+S
260 (38%) (difference -15% [95%CI -30, -0.1], p=0.07). (Table 3)

261
262
263

Table 3. Prevalence of hearing loss in the +P versus +S groups, stratified by allocation to three primary course PCV schedules (_PPP, _SSS, and SSSP) at age 18 months

Primary course Booster dose	PPP			SSS			SSSP			TOTAL
	+P	+S		+P	+S		+P	+S		
N	80	63		85	91		65	76		460
Category of hearing loss	n (%)	n (%)	Diff [95%CI] p value	n (%)	n (%)	Diff [95%CI] p value	n (%)	n (%)	Diff [95%CI] p value	
None (< 20dB)	26 (33%)	17 (27%)	6% [-10, 21] 0.58	31 (36%)	25 (27%)	9% [-5, 23] 0.26	26 (40%)	25 (33%)	7% [-9, 23] 0.48	150 (33%)
Mild (21-30 dB)	31 (39%)	23 (37%)	2% [-14, 18] 0.86	31 (36%)	37 (41%)	-4% [-19, 10] 0.64	24 (37%)	22 (29%)	8% [-7, 24] 0.37	168 (37%)
Moderate (31-60 dB)	23 (29%)	23 (37%)	-8% [-23, 8] 0.37	23 (27%)	29 (32%)	-5% [-18, 9] 0.51	15 (23%)	29 (38%)	-15% [-30, -0.1] 0.069	142 (31%)

264

265 Fluctuating hearing loss was examined using data from children who had hearing tests at two or
 266 more consecutive 6-monthly assessments. Overall, at initial assessment the proportion of hearing tests
 267 that found no hearing loss, mild, or moderate hearing loss was similar (35%, 36%, 29%, respectively)
 268 to 6-monthly follow-up (38%, 36%, 25%, respectively). However, transitions in hearing status were
 269 more dynamic than revealed by point prevalence: of 73 children with no hearing loss initially, 51% had
 270 no hearing loss at follow-up, 37% transitioned to mild-, and 12% to moderate- hearing loss. Of 76
 271 children with mild hearing loss initially, 32% transitioned to no hearing loss, 42% had persisting mild
 272 hearing loss, 26% transitioned to moderate hearing loss, and 1% to severe hearing loss. Of 61 children
 273 with moderate hearing loss initially, 33% transitioned to no hearing loss, 28% transitioned to mild
 274 hearing loss, and 39% had persisting moderate hearing loss. (Table 4)

275 Table 4. Transitions between consecutive 6-monthly hearing assessments
 276

Hearing loss category after 6 months:	Normal: <20 dB	Mild: 21 to 30 dB	Moderate: 31 to 60 dB	Severe: 61 to 90 dB	Total
Hearing loss category at initial assessment:					
Normal: <20 dB	37/73 51%	27 37%	9 12%	0	73 (35%)
Mild: 21 to 30 dB	24/77 31%	32 42%	20 26%	1 (1%)	77 (36%)
Moderate: 31 to 60 dB	20 33%	17 28%	24 39%	0	61 (29%)
Total	81 (38%)	76 (36%)	53 (25%)	1 (0.5%)	211 (100%)

277

278 Discussion

279 To our knowledge this is the first study globally to evaluate hearing loss outcomes in an RCT of head-
 280 to-head or mixed schedule PCVs. This is also the first prospective longitudinal community-based study
 281 of scheduled hearing tests in First Nations children from age 12 to 36 months. A literature search for
 282 studies of either PCV13 or PHiD-CV10 that report either otitis media or hearing-related outcomes,[13]
 283 was repeated for the period 2019 to 2023; of 54 identified studies, none reported hearing outcomes. A
 284 recent 2020 Cochrane review of PCVs for prevention of acute otitis media did not report hearing
 285 outcomes.[15] Other head-to-head RCTs compare immunogenicity of different PCV schedules or
 286 formulations[16, 17] and impact on pneumococcal[18] and NTHi carriage[16] but impacts on hearing
 287 have not been included.

288 Unexpectedly, this report focussing on hearing outcomes found that, contrary to our hypotheses, the
289 children assessed in the +P group had better hearing compared to the +S group at age 18 months. The
290 -3 dB difference in mean hearing level is of unknown clinical value. However, the -19% difference in
291 prevalence of moderate hearing loss and gain of 19% having no hearing loss is likely to benefit many
292 First Nations children, particularly if this is sustained to age 36 months. In addition, around two-thirds
293 of the children assessed at age 18 months met Hearing Australia criteria for hearing assistance,[11] and
294 the proportion was again lower in the +P group at age 18 months (62% versus 76%). At later ages
295 vaccine group differences in hearing persisted. Analysis stratified by the primary course head-to-head
296 and combination schedules (the PREVIX_COMBO RCT)[5] suggested that slightly better hearing in
297 the +P group was present across all primary schedules and was greatest in the SSSP+P versus SSSP+S
298 comparison. These unique findings are difficult to explain and should be interpreted with caution as not
299 all randomised participants received hearing assessments.

300 A limitation of our study is small sample size for this secondary outcome,[19] although there were
301 no boost-group differences in rate of loss-to-follow-up, nor participant characteristics or risk factors at
302 any age. The high event rate somewhat compensates for loss-to-follow-up and may increase confidence
303 in the apparent vaccine group difference in hearing detected at primary endpoint age 18 months. Given
304 the paucity of published data from vaccine trials to support or refute our findings, further investigation
305 of biological plausibility is warranted, particularly as higher valency vaccines become available.[20]

306 Our systematic review identified an almost complete absence of published contemporary (post
307 PCVera) data on the prevalence and persistence of hearing loss in very young First Nations children.[21]
308 In addition, data from the NT hearing outreach services show that only 11% of services (either
309 audiology, Clinical Nurse Specialist, or ear, nose and throat (ENT) teleotology) were provided to
310 children under age 3 years.[22] Of 1,741 First Nations children who received audiology services, 56
311 (3%) were under age 3 years and of these 17 (31%) had some level of hearing loss.

312 The systematic review[21] and national otitis media guidelines[13] also highlight the paucity of
313 prevalence studies and absence of published intervention studies that address this crisis. In 2022 and
314 2023, the first community-based prevalence studies of hearing loss in First Nations children living in
315 urban settings were published; one identified that at age 12 months, 69% of 67 children tested had

316 hearing loss, including 24 (36%) with moderate hearing loss.[23] The second, larger study which
317 excluded children under age 3 years obtained hearing data from 1087 (median age 8.2 years) of 1669
318 children enrolled; 279 (25.7%) had hearing loss.[24] Neither study was an evaluation of hearing loss
319 rehabilitation or prevention strategies.

320 Using combined vaccine group data, our key findings identified for the first time the high prevalence
321 of persistent and fluctuating mild- moderate hearing loss throughout early childhood, from 75% at age
322 12 months to 53% at age 36 months. In particular the high prevalence of moderate hearing loss, defined
323 by the World Health Organization as disabling for children,[10] which was 42% at age 12 months,
324 declining slowly to 19% at age 36 months.

325 These findings place many children in need of hearing assistance according to the Hearing Australia
326 threshold of ≥ 23.3 dB.[11] Also, according to national OM Guidelines,[13] at ages 12 to 30 months,
327 around 30% children met criteria for ENT consultation, based on the mean hearing level in the better
328 ear of >30 dB.

329 Transitions in level of hearing loss between consecutive 6-monthly visits, despite stable prevalence
330 rates at each timepoint, confirm the fluctuating nature of conductive hearing loss in this age group. This
331 has practical implications that support the shift from screening programs to surveillance, commencing
332 within first year of life.[25]

333 A strength of our study is that all hearing tests were performed in sound-treated facilities by
334 paediatric audiologists at scheduled study visits, regardless of clinical presentation. However, the
335 majority of hearing tests were VROA for which the minimum test level varies according to test
336 environment and child. If the minimum test level available was 20 to 25 dB, children with a true hearing
337 level below test limits could be misidentified as having mild hearing loss using our study definitions,
338 producing a false positive and over-inflating the prevalence of mild hearing loss as determined by
339 VROA.

340 From primary health care to specialist services there are huge shortfalls that disrupt a child's hearing
341 care pathway.[26] At December 2022, there were 3,265 Indigenous children and young people on the
342 wait list for fly-in/fly-out audiology outreach services and 2,284 on the ENT teleotology wait list.[22]

343 As mentioned, in 2022 very few outreach services were for children under age 3 years, and ENT
344 surgeries were rarely performed (4% of all ENT services were for grommets).[22]

345 This report of the extraordinarily high prevalence of preventable hearing loss in First Nations
346 children highlights the need for effective social and public health reforms with greater investment in
347 interventions that target social determinants, namely more preventative models.[27] Others have
348 demonstrated the inequalities in ENT service provision between Aboriginal and non-Aboriginal
349 children, attributed to socioeconomic status and geographical isolation.[28] In the US, social
350 deprivation limits children's access to appropriate medical and surgical treatment for their ear disease
351 and increases odds of severe complications.[29] Unfortunately studies of interventions that address
352 social determinants will be difficult and few that report otitis media outcomes have been published or
353 show a benefit.[30] Our research program is currently evaluating a primary health care workforce
354 enhancement strategy (the Hearing for Learning Initiative) of remote on-country training and
355 employment of ear health facilitators which could provide a sustainable, culturally appropriate and safe
356 model to detect and prevent disabling hearing loss, and support children who have hearing
357 problems.[31, 32]

358 **DECLARATIONS**

359 **Ethics approval and consent to participate**

360 Ethical approval has been obtained from Human Research Ethics Committees of the Northern Territory
361 Department of Health and Menzies School of Health Research (NHMRC Reg no: EC00153), the
362 Central Australian HREC (NHMRC Reg no: EC00155) and West Australian Aboriginal Health Ethics
363 Committee (WAAHEC- 377-12/2011). Parents or guardians provided signed informed consent for their
364 infant's participation.

365 **Availability of data/Data sharing**

366 Data collected for the study that underlie the results reported in this Article, including individual
367 participant data and a data dictionary defining each field in the set, will be made available after
368 de-identification. No additional, related documents will be available, and the study protocols have been
369 published. Data will be available upon request to the Senior Data Manager at the Menzies School of
370 Health Research (datamanagement@menzies.edu.au). Data will be shared with investigators whose
371 proposed use of the data has been approved by the ethics committees of NT Health, Menzies School of
372 Health Research, WA Department of Health, and WA Aboriginal Health Ethics Committee, and
373 approved by the Menzies' Child Health Division's Australian First Nations Reference Group, for
374 analyses that meet criteria for excellence in research with Aboriginal and Torres Strait Islander people,
375 and with an institutional-signed and investigator signed data sharing research agreement.

376 **Competing interests (use author initials)/Declaration of interests**

377 **AJL** received funds from NHMRC paid to the institution, and GSK provided materials for
378 immunogenicity assays. **AJL** received funds from Merck Sharp and Dohme for analysis of
379 pneumococcal carriage, payment to institution. **ABC** served as advisor on a Data Safety Monitoring
380 Board for an unlicensed vaccine (GlaxoSmithKline) and an unlicensed monoclonal antibody
381 (AstraZeneca), was an adviser on an unlicensed molecule for chronic cough (Merck); and has multiple
382 project grants and a Centre of Research Excellence relating to various aspects of bronchiectasis in
383 children from the National Health and Medical Research Council. **ABC** received Royalties or licences
384 as an author of cough and bronchiectasis topics, and Partial reimbursement for airfares as a speaker for
385 European Respiratory Society. All payments were to the institution. **PM** served on a data safety and
386 monitoring board for the Novavax COVID-19 vaccine. **JB** provided a report to MSD Australia.
387 All other authors (**DL**, **CB-J**, **HS-V**, **MB**, **MC**, **PL**, **PSM**, **PT**,) declare no competing interests.

388 **Role of funding source**

389 The funders had no role in study design, data collection, data analysis, data interpretation, or writing of
390 the report. The corresponding author and statistician had full access to all the data and **AJL** had
391 responsibility for the decision to submit for publication. **AJL** was not paid by any agency to write this
392 article.

393 **Data safety monitoring**

394 The study was overseen by an independent Data Safety and Monitoring Board (iDSMB).

395 **Author contributions**

396 **AJL** (Principal Investigator, PI) conceived the study, led funding applications, obtained HREC approval
397 and other regulatory approvals, undertook consultations, reporting and had overseen day to day
398 management and implementation of the trials, managed, had direct access to and verified the reported
399 data, analysed and interpreted the data, created tables and figures, wrote the first draft and final version
400 of manuscript. **NW** managed the trial, participant recruitment and retention, specimen collection,
401 reported to Ethics committees and data safety monitoring board, managed quality of data and read the
402 final version of the manuscript. **BA** assisted participant recruitment and retention, specimen collection,
403 managed quality of data and read the final version of the manuscript. **JB** managed microbiology and
404 serology collections, data base and data quality, and read the final version of the manuscript. **EKM**
405 advised on study design, assisted with funding application, participated in investigator meetings,
406 advised on risk management and read the final version of the manuscript. **MS** advised on study design,
407 assisted with funding application, participated in investigator meetings, advised on risk management
408 and read the final version of the manuscript. **PJT** advised on study design, assisted with funding
409 application, participated in investigator meetings, advised on risk management and read the final
410 version of the manuscript. **PM** advised on study design, assisted with funding application, participated
411 in investigator meetings, advised on risk management and read the final version of the manuscript. **HS-**
412 **V** advised on study design, assisted with funding application, participated in investigator meetings,

413 advised on microbiology protocols, and reviewed the final version of the manuscript. SS advised on
414 study design, assisted with funding application, participated in investigator meetings, advised on
415 laboratory protocols, particularly microbiology, and reviewed the final version of the manuscript. VO
416 participated in investigator meetings, wrote the final statistical analysis plans, had direct access to and
417 verified the reported data, generated tables and figures and read the final version of the manuscript. MC
418 advised on study design, assisted with funding application, participated in investigator meetings, wrote
419 the initial statistical analysis plans in the protocols, analysed data, generated tables and figures and read
420 the final version of the manuscript. DL advised on study design, assisted with funding application,
421 participated in investigator meetings, advised on tables and figures and read the final version of the
422 manuscript. CB-J advised on interpretation of audiology data and read the final version of the
423 manuscript. MB advised on study design, assisted with funding application, participated in investigator
424 meetings, advised on tables and figures and read the final version of the manuscript. PL advised on
425 laboratory protocols, particularly immunogenicity, and read the final version of the manuscript. RMA
426 advised on study design, assisted with funding application, participated in investigator meetings,
427 advised on tables and figures and read the final version of the manuscript. TS advised on study design,
428 assisted with funding application, participated in investigator meetings, advised on tables and figures
429 and read the final version of the manuscript. VK advised on study design, assisted with funding
430 application, participated in investigator meetings, advised on tables and figures and read the final
431 version of the manuscript. JC advised on study design, assisted with funding application, participated
432 in investigator meetings, advised on tables and figures and read the final version of the manuscript.
433 ABC advised on study design, assisted with funding application, participated in investigator meetings,
434 advised on tables and figures and read the final version of the manuscript. PSM advised on study design,
435 assisted with funding application, participated in investigator meetings, advised on risk management
436 and provided day to day supervision of clinical training, and read the final version of the manuscript.

437 **Acknowledgements**

438 Sources of funding were the Australian NHMRC (National Health and Medical Research Council
439 (GNT605810, GNT1046999, GNT1120353) and GlaxoSmithKline (donation of reagents). AJL was not
440 paid by any agency to write this article. We thank the many families living in remote communities in
441 northern Australia who participated in the PREVIX_COMBO and PREVIX_BOOST randomised
442 controlled trials. We thank the many research nurses, audiologists, laboratory staff, and others who
443 worked on the trials.

444

445

446 References

- 447 1. Su JY, Guthridge S, He VY, Howard D, Leach AJ. The impact of hearing impairment on early
448 academic achievement in Aboriginal children living in remote Australia: a data linkage study. *BMC*
449 *Public Health*. 2020;20(1):1521. Epub 2020/10/09. doi: 10.1186/s12889-020-09620-6. PubMed
450 PMID: 33028291; PubMed Central PMCID: PMC33028291.
- 451 2. Leach AJ, Wigger C, Hare K, Hampton V, Beissbarth J, Andrews R, et al. Reduced middle ear
452 infection with non-typeable *Haemophilus influenzae*, but not *Streptococcus pneumoniae*, after
453 transition to 10-valent pneumococcal non-typeable *H. influenzae* protein D conjugate vaccine. *BMC*
454 *pediatrics*. 2015;15(1):162-75. Epub 2015/10/21. doi: 10.1186/s12887-015-0483-8. PubMed PMID:
455 26482232; PubMed Central PMCID: PMC4615539.
- 456 3. Leach AJ, Wigger C, Beissbarth J, Woltring D, Andrews R, Chatfield MD, et al. General health,
457 otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal
458 children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate
459 vaccines. *Int J Pediatr Otorhinolaryngol*. 2016;86:224-32. Epub 2016/06/05. doi:
460 10.1016/j.ijporl.2016.05.011. PubMed PMID: 27260611.
- 461 4. Leach AJ, Mulholland EK, Santosham M, Torzillo PJ, McIntyre P, Smith-Vaughan H, et al.
462 Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal *Haemophilus*
463 *influenzae* protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-
464 6 months: PREVIX_COMBO, a 3-arm randomised controlled trial. *Vaccine: X*. 2021;7:100086. doi:
465 10.1016/j.jvacx.2021.100086.
- 466 5. Leach AJ, Mulholland EK, Santosham M, Torzillo PJ, Brown NJ, McIntyre P, et al.
467 Pneumococcal conjugate vaccines PREVENAR13 and Synflorix in sequence or alone in high-risk
468 Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial. *BMJ open*.
469 2015;5(1):e007247-57. Epub 2015/01/18. doi: 10.1136/bmjopen-2014-007247. PubMed PMID:
470 25596202.
- 471 6. Leach AJ, Wilson N, Arrowsmith B, Beissbarth J, Mulholland EK, Santosham M, et al.
472 Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-
473 valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming
474 schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials. *The Lancet Infectious*
475 *diseases*. 2022. Epub 2022/07/01. doi: 10.1016/s1473-3099(22)00272-9. PubMed PMID: 35772449.
- 476 7. Oguoma VM, Wilson N, Mulholland K, Santosham M, Torzillo P, McIntyre P, et al. 10-Valent
477 pneumococcal non-typeable *H. influenzae* protein D conjugate vaccine (PHiD-CV10) versus 13-valent
478 pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection
479 from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised
480 controlled trial. *BMJ open*. 2020;10(5):e033511. doi: 10.1136/bmjopen-2019-033511.
- 481 8. Beissbarth J, Wilson N, Arrowsmith B, Binks MJ, Oguoma VM, Lawrence K, et al.
482 Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable
483 *Haemophilus influenzae* protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal
484 conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled
485 trial. *Vaccine*. 2021;39(16):2264-73. doi: 10.1016/j.vaccine.2021.03.032.
- 486 9. Leach AJ, Wilson N, Arrowsmith B, Beissbarth J, Mulholland EK, Santosham M, et al. Otitis
487 media at 6-monthly assessments of Australian First Nations children between ages 12–36 months:
488 Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.
489 *International Journal of Pediatric Otorhinolaryngology*. 2023;175:111776. doi:
490 10.1016/j.ijporl.2023.111776.
- 491 10. Olusanya BO, Davis AC, Hoffman HJ. Hearing loss grades and the International classification
492 of functioning, disability and health. *Bulletin of the World Health Organization*. 2019;97(10):725-8.
493 doi: 10.2471/blt.19.230367.
- 494 11. Australian Government. Program Standard - Minimum Hearing Loss Threshold (MHLT)
495 Guidelines. In: Health Do, editor. 2022.

- 496 12. Central Australian Rural Practitioners Association (CARPA). Central Australian Rural
497 Practitioners Association (CARPA) Standard Treatment Manual. 7th edition. ed. Alice Springs,
498 Australia: Central Australian Rural Practitioners Association (CARPA); 2017 2017.
- 499 13. Leach AJ, Morris PS, Coates HL, Nelson S, O'Leary SJ, Richmond PC, et al. Otitis media
500 guidelines for Australian Aboriginal and Torres Strait Islander children: summary of
501 recommendations. *Med J Aust.* 2021;214(5):228-33. Epub 2021/03/01. doi: 10.5694/mja2.50953.
502 PubMed PMID: 33641192.
- 503 14. Statacorp. Stata Statistical Software: Release 15. College Station, Texas:. Stata Corporation.
504 2017.
- 505 15. de Sévaux JL, Venekamp RP, Lutje V, Hak E, Schilder AG, Sanders EA, et al. Pneumococcal
506 conjugate vaccines for preventing acute otitis media in children. *The Cochrane database of*
507 *systematic reviews.* 2020;11(11):Cd001480. Epub 2020/11/25. doi:
508 10.1002/14651858.CD001480.pub6. PubMed PMID: 33231293.
- 509 16. Pomat WS, van den Biggelaar AHJ, Wana S, Francis JP, Solomon V, Greenhill AR, et al. Safety
510 and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: A randomized
511 controlled trial of 10-valent and 13-valent pneumococcal conjugate vaccine in Papua New Guinean
512 Infants. *Clin Infect Dis.* 2019;68(9):1472-81. Epub 2018/09/06. doi: 10.1093/cid/ciy743. PubMed
513 PMID: 30184183; PubMed Central PMCID: PMC6481999.
- 514 17. Madhi SA, Mutsaerts EA, Izu A, Boyce W, Bhikha S, Ikulinda BT, et al. Immunogenicity of a
515 single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or
516 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised,
517 non-inferiority trial. *The Lancet Infectious diseases.* 2020;20(12):1426-36. Epub 2020/08/29. doi:
518 10.1016/s1473-3099(20)30289-9. PubMed PMID: 32857992; PubMed Central PMCID:
519 PMC67689288.
- 520 18. Smith-Vaughan H, Temple B, Trang Dai VT, Hoan PT, Loc Thuy HN, Phan TV, et al. Effect of
521 different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in
522 Vietnamese infants: results from a randomised controlled trial. *Lancet Reg Health West Pac.*
523 2023;32:100651. Epub 2023/02/15. doi: 10.1016/j.lanwpc.2022.100651. PubMed PMID: 36785850;
524 PubMed Central PMCID: PMC69918756.
- 525 19. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards
526 of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials
527 (RCTs) published in medical journals. *The Cochrane database of systematic reviews.*
528 2012;11:MR000030. Epub 2012/11/16. doi: 10.1002/14651858.MR000030.pub2. PubMed PMID:
529 23152285.
- 530 20. Perdrizet J, Farkouh RA, Horn EK, Hayford K, Sings HL, Wasserman MD. The broader impacts
531 of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate
532 vaccines. *Expert review of vaccines.* 2022;1-13. Epub 2022/02/23. doi:
533 10.1080/14760584.2022.2040989. PubMed PMID: 35191368.
- 534 21. Kaspar A, Leach AJ. Hearing loss among Australian Aboriginal infants and toddlers: A
535 systematic review. *Public Health in Practice.* 2020;1. doi: 10.1016/j.puhip.2020.100048.
- 536 22. Australian Institute of Health and Welfare (2023). Hearing health outreach services for
537 Aboriginal and Torres Strait Islander children in the Northern Territory: July 2012 to December 2022.
538 Canberra: AIHW, 2023.
- 539 23. Veselinović T, Weeks SA, Swift VM, Lehmann D, Brennan-Jones CG. High prevalence of
540 hearing loss in urban Aboriginal infants: the Djaalinj Waakinj cohort study. *Medical Journal of*
541 *Australia.* 2022;217(1):46-7. doi: 10.5694/mja2.51534.
- 542 24. DeLacy J, Burgess L, Cutmore M, Sherriff S, Woolfenden S, Falster K, et al. Ear health and
543 hearing in urban Aboriginal children. *Australian and New Zealand journal of public health.*
544 2023;47(4):100075. Epub 20230728. doi: 10.1016/j.anzjph.2023.100075. PubMed PMID: 37517360.
- 545 25. Harkus S, Marnane V, O'Keeffe I, Kung C, Ward M, Orr N, et al. Routine ear health and
546 hearing checks for Aboriginal and Torres Strait Islander children aged under 6 years attending

- 547 primary care: a national consensus statement. *Med J Aust.* 2023. Epub 20230916. doi:
548 10.5694/mja2.52100. PubMed PMID: 37716709.
- 549 26. Hearing Australia. 2020-Demographics-of-Aided-Young-Australians-at-31-December-2020.
550 2021.
- 551 27. Delacy J, Dune T, Macdonald JJ. The social determinants of otitis media in Aboriginal children
552 in Australia: are we addressing the primary causes? A systematic content review. *BMC Public Health.*
553 2020;20(1). doi: 10.1186/s12889-020-08570-3.
- 554 28. Falster K, Randall D, Banks E, Eades S, Gunasekera H, Reath J, et al. Inequalities in ventilation
555 tube insertion procedures between Aboriginal and non-Aboriginal children in New South Wales,
556 Australia: a data linkage study. *BMJ open.* 2013;3(11):e003807. Epub 2013/11/29. doi:
557 10.1136/bmjopen-2013-003807. PubMed PMID: 24285631; PubMed Central PMCID:
558 PMC3845074.
- 559 29. Qian ZJ, Rehkopf DH. Association Between Social Disadvantage and Otitis Media Treatment
560 in US Children With Commercial Insurance. *JAMA Otolaryngology–Head & Neck Surgery.*
561 2023;149(1):7-14. doi: 10.1001/jamaoto.2022.3560.
- 562 30. NSW Department of Health. Closing the gap: 10 Years of *Housing for Health* in NSW. An
563 evaluation of a healthy housing intervention. Aboriginal Environmental Health Unit. Population
564 Health Division. 2010 2010. Report No.
- 565 31. Campbell L, Reath J, Hu W, Gunasekera H, Askew D, Watego C, et al. The socioemotional
566 challenges and consequences for caregivers of Aboriginal and Torres Strait Islander children with
567 otitis media: A qualitative study. *Health Expect.* 2022. Epub 2022/03/18. doi: 10.1111/hex.13476.
568 PubMed PMID: 35297133.
- 569 32. Kong K, Cass A, Leach AJ, Morris PS, Kimber A, Su J-Y, et al. A community-based service
570 enhancement model of training and employing Ear Health Facilitators to address the crisis in ear and
571 hearing health of Aboriginal children in the Northern Territory, the Hearing for Learning Initiative
572 (the HfLI): study protocol for a stepped-wedge cluster randomised trial. *Trials.* 2021;22(1):403-22.
573 doi: 10.1186/s13063-021-05215-7.

574